Declaration and Consent for Sessions 3 and 4 at BTOG National Trials Meeting 2026 For BTOG National Trials Meeting 2026 Sessions 3 and 4 Industry-Led Sessions The presentations in Session 3 & 4 are provided in response to specific requests from the BTOG steering committee and they may contain pre-licence information and is non-promotional. The aim of the session is to provide an overview on clinical trials led by the pharmaceutical industry. Although these are commercial trials, the content is non-promotional and does not constitute pre-license promotion by the pharmaceutical industry. Name(Required) First Last Job Title(Required)Place of Work(Required)Today's Date(Required) Consent(Required) Declaration - If left unchecked or not completed please note you will not be allowed to attend Sessions 3 and 4. I understand that checking this box serves as an electronic signature to confirm that I: Consent to hear the data or information presented by the 6 companies: AstraZeneca, BioNTech, Boehringer Ingelheim, Lilly, MSD and Roche, presented in Sessions 3 and 4; and Understand that my full name, job title and place of work will be included on an attendee list provided by BTOG to the 6 companies for their records; and Agree that I will not take photos of any presentation slides and will not share any data or information on social media or outside of the meeting. If an individual company gives permission to share data or information with colleagues outside of the meeting, they will confirm this during their presentation.
